Full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Professor Ellen Kapiteijn, MD, from Leiden University Medical Centers, have been published in The Lancet Oncology. The trial randomized 76 patients with metastatic uveal melanoma (mUM) to percutaneous hepatic perfusion (PHP) with melphalan (Delcath's CHEMOSAT Hepatic Delivery System) alone or in combination with ipilimumab plus nivolumab. The combination arm demonstrated a 1-year progression-free survival (PFS) of 54.7% compared to 15.8% for PHP-alone (adjusted HR 0.34; 95% CI 0.19-0.60; p=0.0002). Median PFS was 12.8 months in the combination arm versus 8.3 months in the PHP-alone arm. Overall Survival (OS) median was 23.1 months in the combination arm versus 19.6 months in the PHP-alone arm (HR 0.39; 95% CI 0.20-0.77; p=0.0065). The 2-year OS rate was 49.6% for the combination arm compared to 22.1% for PHP-alone. Objective Response Rate (ORR) was 76.3% in the combination arm versus 39.5% in the PHP-alone arm, with a Complete Response (CR) rate of 13% versus 3%. Grade 3 or higher treatment-related adverse events occurred significantly more frequently in the combination arm (82%) than in the PHP-alone arm (41%); p=0.0006, which was similar to the rate reported in the FOCUS trial (81%). Common grade 3/4 events included thrombocytopenia (34% vs 14%), leukopenia (26% vs 14%), g-glutamyl transferase increase (18% vs 8%), and anemia (13% vs 3%). Most adverse events were self-limiting or manageable with standard supportive care, and no new safety signals were identified. One treatment-related death (immune-related triple M syndrome) occurred in the combination arm.